Obesity Clinical Trial
Official title:
The Effect of Bitter, Umami and Sweet Tastants on Food Intake
Rationale: The appearance of tastants in the small intestine can result in the activation of
a negative feedback mechanism from different parts of the intestine to the stomach, the
small intestine and to the central nervous system. These processes inhibit food processing,
appetite sensations and food intake, and furthermore they increase feelings of satiety and
satiation. We will investigate the effects of intraduodenal infusion of quinine 75mg
(bitter), rebaudioside A 540mg (sweet), monosodium glutamate 2g (umami), a combination of
these tastants (quinine, rebaudioside A, monosodium glutamate) and placebo (5 test days in
total) on ad libitum food intake, satiation and in vivo release of the gut satiety peptides
CCK and GLP-1.
Study design: To assess the effect of intraduodenal infusion of single ingredients and a
combination of tastants (bitter, umami and sweet) on ad libitum food intake.
Secondary Objective(s):
1. To investigate the effect of intraduodenal delivery of a combination of tastants on
satiation.
2. To assess the effect of intraduodenal delivery of a combination of tastants on
gastrointestinal hormone release.
3. To assess the effects of the tastants quinine, rebaudioside A and monosodium glutamate
on the parameters as mentioned under the primary objective, and under secondary
objectives 1 and 2.
4. To compare the effects, as mentioned under the primary objective, and under secondary
objectives 1 and 2, of the combination of tastants to those of the three single
tastants quinine, rebaudioside A and monosodium glutamate.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
| Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
| Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
| Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
| Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
| Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
| Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
| Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
| Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
| Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
| Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
| Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
| Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
| Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
| Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |